First Time Loading...

Samsung Biologics Co Ltd
KRX:207940

Watchlist Manager
Samsung Biologics Co Ltd Logo
Samsung Biologics Co Ltd
KRX:207940
Watchlist
Price: 781 000 KRW Market Closed
Updated: May 15, 2024

Net Margin
Samsung Biologics Co Ltd

23.2%
Current
24%
Average
1.1%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
23.2%
=
Net Income
857.7B
/
Revenue
3.7T

Net Margin Across Competitors

Country Company Market Cap Net
Margin
KR
Samsung Biologics Co Ltd
KRX:207940
55.6T KRW
23%
US
Thermo Fisher Scientific Inc
NYSE:TMO
231.7B USD
14%
US
Danaher Corp
NYSE:DHR
195.1B USD
18%
US
Agilent Technologies Inc
NYSE:A
45.2B USD
18%
US
IQVIA Holdings Inc
NYSE:IQV
42.4B USD
9%
CH
Lonza Group AG
SIX:LONN
38.3B CHF
10%
US
Mettler-Toledo International Inc
NYSE:MTD
32.5B USD
21%
IE
ICON PLC
NASDAQ:ICLR
26.6B USD
8%
US
West Pharmaceutical Services Inc
NYSE:WST
25.6B USD
19%
FR
Sartorius Stedim Biotech SA
PAR:DIM
19.8B EUR
9%
US
Waters Corp
NYSE:WAT
21.4B USD
21%
Samsung Biologics Co Ltd
KRX:207940
Country KR
Market Cap 55.6T KRW
Net Margin
23%
Thermo Fisher Scientific Inc
NYSE:TMO
Country US
Market Cap 231.7B USD
Net Margin
14%
Danaher Corp
NYSE:DHR
Country US
Market Cap 195.1B USD
Net Margin
18%
Agilent Technologies Inc
NYSE:A
Country US
Market Cap 45.2B USD
Net Margin
18%
IQVIA Holdings Inc
NYSE:IQV
Country US
Market Cap 42.4B USD
Net Margin
9%
Lonza Group AG
SIX:LONN
Country CH
Market Cap 38.3B CHF
Net Margin
10%
Mettler-Toledo International Inc
NYSE:MTD
Country US
Market Cap 32.5B USD
Net Margin
21%
ICON PLC
NASDAQ:ICLR
Country IE
Market Cap 26.6B USD
Net Margin
8%
West Pharmaceutical Services Inc
NYSE:WST
Country US
Market Cap 25.6B USD
Net Margin
19%
Sartorius Stedim Biotech SA
PAR:DIM
Country FR
Market Cap 19.8B EUR
Net Margin
9%
Waters Corp
NYSE:WAT
Country US
Market Cap 21.4B USD
Net Margin
21%

Profitability Report

View the profitability report to see the full profitability analysis for Samsung Biologics Co Ltd.

Full Profitability Report

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
23.2%
=
Net Income
857.7B
/
Revenue
3.7T
What is the Net Margin of Samsung Biologics Co Ltd?

Based on Samsung Biologics Co Ltd's most recent financial statements, the company has Net Margin of 23.2%.

ALPHA SPREAD
Join more than 137,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.